| name | Terbinafine Systemic |
| classification | Antifungal, Allylamine derivative |
| pharmacokinetics | Terbinafine is well absorbed orally, with peak plasma concentrations typically reached within 1-2 hours. The drug is primarily metabolized in the liver and the major metabolites are inactive. The elimination half-life is approximately 10-12 hours. It is distributed throughout the body, including the skin, nails, and hair follicles. |
| suggested dosage | | general | Dosage should be determined by a physician and will depend on the specific indication (e.g., toenail, fingernail, or skin infections). | | examples | | 1 | | indication | Onchomycosis (nail fungus): | | dosage | 250 mg orally once daily for 6-12 weeks, depending on the severity of the infection and the response. It can be taken with or without food |
| | 2 | | indication | Tinea capitis (scalp ringworm): | | dosage | 250 mg orally once daily for 4-6 weeks. |
|
| | important note | Consult a medical professional for proper dosage and duration of treatment. Do not adjust the dosage without consulting your physician. |
|
| indications | Terbinafine is primarily used to treat various superficial fungal infections, including: onychomycosis (nail fungus), tinea pedis (athlete's foot), tinea corporis (ringworm), tinea cruris (jock itch), and tinea capitis (scalp ringworm). |
| safety in pregnancy | Limited data is available. Terbinafine crosses the placenta. Use during pregnancy should only be considered if the potential benefits outweigh the potential risks. Consult a healthcare professional for individual risk assessment. |
| safety in breastfeeding | Terbinafine may be excreted in breast milk. If breastfeeding, careful consideration of the potential risks and benefits is required. |
| side effects | | 1 | Gastrointestinal issues (nausea, vomiting, diarrhea, abdominal pain) | | 2 | Headache | | 3 | Skin rash | | 4 | Alopecia (hair loss) | | 5 | Peripheral neuropathy | | 6 | Elevated liver enzymes (rare) | | 7 | Hypersensitivity reactions (rare) |
|
| alternative drugs | |
| contraindications | Known hypersensitivity to terbinafine or other allylamine derivatives, severe hepatic impairment, and concomitant use with drugs that significantly affect liver function. |
| interactions | Terbinafine may interact with several other medications. Consult a physician about concurrent use of other medications, including but not limited to, medications that affect the liver, CYP3A4 substrates, or P-glycoprotein inhibitors. |
| warnings and precautions | | 1 | Monitor liver function tests, particularly during prolonged treatment. | | 2 | Instruct the patient to report any signs of skin rash, allergic reactions, or unusual bleeding. | | 3 | Avoid use in patients with severe renal impairment unless absolutely necessary, with close monitoring. | | 4 | Patients should be advised to avoid driving or operating heavy machinery if they experience dizziness or any other adverse effect. | | 5 | Not recommended for use in children due to potential for hepatotoxicity. |
|
| additional information | Terbinafine's long treatment duration for onychomycosis requires patient adherence and follow-up appointments. It may take several months to see complete resolution of nail infection. |
| patient specific considerations | | age | While terbinafine is used in adults, specific recommendations are necessary for different patient populations. Consult with a physician about the use in a 25-year-old male. | | weight | Patient weight is not a significant factor in determining dosage for Terbinafine, but the physician will consider all factors when determining the best treatment plan. | | important note | This information is for general knowledge and educational purposes only, and does not constitute medical advice. It is essential to consult with a healthcare professional for any health concerns or before making any decisions related to medication use. |
|
